Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Size, Share, Trends, Growth Outlook

Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market is estimated to increase at a growth rate of 10.8% CAGR over the forecast period from 2024 to 2030.

The global Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Patch Pumps (Basal, Bous, Basal and bolus), Tethered pumps (Insulin reservoir and cartridges, Insulin set insertion devices, Battery)), By Patient (Type 1 Diabetes, Type 2 Diabetes).

An Introduction to Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market in 2024

The Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market comprises medical devices used for continuous and automated delivery of insulin to manage diabetes mellitus. CSITD devices, such as insulin pumps and patch pumps, deliver precise insulin doses subcutaneously throughout the day, replacing traditional multiple daily injections (MDI) and offering improved glycemic control, convenience, and lifestyle flexibility for patients with diabetes. Market growth is driven by the increasing prevalence of diabetes, the shift towards personalized diabetes management, technological advancements in insulin delivery systems, and the growing adoption of CSITD devices for better glucose management and patient outcomes.

Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Competitive Landscape

The global Continuous Subcutaneous Insulin Therapy Devices (CSITD) Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Continuous Subcutaneous Insulin Therapy Devices (CSITD) Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Continuous Subcutaneous Insulin Therapy Devices (CSITD) Industry include- Cellenovo, CeQur, F. Hoffmann-La Roche Ltd, Insulet Corp, Medtronic Plc, Sooil Development, Tandem Diabetes Care, Valeritas Inc, Ypsomed.

Continuous Subcutaneous Insulin Therapy Devices Market Trend: Integration of Advanced Insulin Delivery Technologies

A prominent trend in the continuous subcutaneous insulin therapy (CSII) devices market is the integration of advanced insulin delivery technologies, offering improved precision, customization, and convenience for individuals with diabetes. Manufacturers are incorporating features such as continuous glucose monitoring (CGM) integration, automated insulin dosing algorithms, and smartphone connectivity into CSII devices to enhance glycemic control, reduce hypoglycemic events, and simplify insulin management for patients. Additionally, advancements in infusion set design, insulin pump algorithms, and user interfaces contribute to enhanced therapy adherence, treatment satisfaction, and quality of life for individuals requiring intensive insulin therapy. This trend towards integration of advanced insulin delivery technologies reflects a shift towards personalized diabetes management, patient empowerment, and enhanced treatment outcomes, driving market growth and innovation in CSII device development.

Continuous Subcutaneous Insulin Therapy Devices Market Driver: Rising Prevalence of Diabetes and Insulin Therapy Adoption

A key driver propelling the continuous subcutaneous insulin therapy devices market is the rising prevalence of diabetes and increasing adoption of insulin therapy among individuals with diabetes worldwide, driven by factors such as aging populations, sedentary lifestyles, and obesity. Diabetes, a chronic metabolic disorder characterized by elevated blood glucose levels, affects millions of individuals globally and poses significant health risks, including cardiovascular disease, kidney failure, and vision loss. As the prevalence of diabetes continues to rise, there is growing demand for intensive insulin therapy options, such as CSII devices, to achieve optimal glycemic control, prevent diabetes-related complications, and improve overall health outcomes. Healthcare providers prioritize individualized treatment approaches and intensive insulin management strategies for patients with diabetes, driving market demand and adoption of CSII devices as essential tools for diabetes management and self-care.

Continuous Subcutaneous Insulin Therapy Devices Market Opportunity: Expansion into Artificial Pancreas Systems and Closed-loop Insulin Delivery

An emerging opportunity in the continuous subcutaneous insulin therapy devices market lies in the expansion into artificial pancreas systems (APS) and closed-loop insulin delivery solutions to address the evolving needs of individuals with diabetes for automated, autonomous insulin management. APS integrate continuous glucose monitoring (CGM) sensors, insulin pumps, and automated dosing algorithms to mimic the physiological function of the pancreas, automatically adjusting insulin delivery in response to real-time glucose fluctuations, minimizing hypoglycemic and hyperglycemic excursions, and optimizing glycemic control. Closed-loop insulin delivery systems offer individuals with diabetes greater flexibility, autonomy, and peace of mind in managing their condition, reducing the burden of diabetes self-management and improving quality of life. By expanding into APS and closed-loop insulin delivery technologies, manufacturers can offer innovative solutions that enhance diabetes care, empower patients to achieve glycemic targets, and address unmet needs in insulin therapy optimization and automation. This presents an opportunity to drive market differentiation, accelerate technology adoption, and advance the standard of care for diabetes management.

Market Share Analysis: Patch Pumps in Continuous Subcutaneous Insulin Therapy Devices is the fastest growing segment in the Continuous Subcutaneous Insulin Therapy Devices industry

Among Continuous Subcutaneous Insulin Therapy Devices, patch pumps are experiencing the fastest growth. These innovative devices offer a convenient and discreet alternative to traditional insulin delivery methods, such as injections or tethered pumps. Patch pumps are typically worn directly on the skin and deliver insulin continuously throughout the day, providing a steady basal rate as well as the ability to deliver bolus doses as needed, making them suitable for both basal and bolus insulin delivery. They are particularly beneficial for patients with type 1 and type 2 diabetes who require insulin therapy, offering greater flexibility, ease of use, and improved adherence to treatment regimens. As the prevalence of diabetes continues to rise globally, driven by factors such as sedentary lifestyles and poor dietary habits, the demand for more advanced and user-friendly insulin delivery devices like patch pumps is expected to increase significantly. Additionally, ongoing technological advancements aimed at enhancing the performance and features of patch pumps are further fueling their growth in the market.

Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Segmentation

By Product
Patch Pumps
-Basal
-Bous
-Basal and bolus
Tethered pumps
-Insulin reservoir and cartridges
-Insulin set insertion devices
-Battery
By Patient
Type 1 diabetes
Type 2 diabetes
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Continuous Subcutaneous Insulin Therapy Devices (CSITD) Companies

Cellenovo
CeQur
F. Hoffmann-La Roche Ltd
Insulet Corp
Medtronic Plc
Sooil Development
Tandem Diabetes Care
Valeritas Inc
Ypsomed
* List not Exhaustive

Reasons to Buy the Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Continuous Subcutaneous Insulin Therapy Devices (CSITD) Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Size Outlook, $ Million, 2021 to 2030
3.2 Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Outlook by Type, $ Million, 2021 to 2030
3.3 Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Outlook by Product, $ Million, 2021 to 2030
3.4 Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Outlook by Application, $ Million, 2021 to 2030
3.5 Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Continuous Subcutaneous Insulin Therapy Devices (CSITD) Industry
4.2 Key Market Trends in Continuous Subcutaneous Insulin Therapy Devices (CSITD) Industry
4.3 Potential Opportunities in Continuous Subcutaneous Insulin Therapy Devices (CSITD) Industry
4.4 Key Challenges in Continuous Subcutaneous Insulin Therapy Devices (CSITD) Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Outlook by Segments
7.1 Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Outlook by Segments, $ Million, 2021- 2030
By Product
Patch Pumps
-Basal
-Bous
-Basal and bolus
Tethered pumps
-Insulin reservoir and cartridges
-Insulin set insertion devices
-Battery
By Patient
Type 1 diabetes
Type 2 diabetes
8 North America Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Analysis and Outlook To 2030
8.1 Introduction to North America Continuous Subcutaneous Insulin Therapy Devices (CSITD) Markets in 2024
8.2 North America Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market size Outlook by Segments, 2021-2030
By Product
Patch Pumps
-Basal
-Bous
-Basal and bolus
Tethered pumps
-Insulin reservoir and cartridges
-Insulin set insertion devices
-Battery
By Patient
Type 1 diabetes
Type 2 diabetes
9 Europe Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Analysis and Outlook To 2030
9.1 Introduction to Europe Continuous Subcutaneous Insulin Therapy Devices (CSITD) Markets in 2024
9.2 Europe Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Size Outlook by Segments, 2021-2030
By Product
Patch Pumps
-Basal
-Bous
-Basal and bolus
Tethered pumps
-Insulin reservoir and cartridges
-Insulin set insertion devices
-Battery
By Patient
Type 1 diabetes
Type 2 diabetes
10 Asia Pacific Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Continuous Subcutaneous Insulin Therapy Devices (CSITD) Markets in 2024
10.2 Asia Pacific Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market size Outlook by Segments, 2021-2030
By Product
Patch Pumps
-Basal
-Bous
-Basal and bolus
Tethered pumps
-Insulin reservoir and cartridges
-Insulin set insertion devices
-Battery
By Patient
Type 1 diabetes
Type 2 diabetes
11 South America Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Analysis and Outlook To 2030
11.1 Introduction to South America Continuous Subcutaneous Insulin Therapy Devices (CSITD) Markets in 2024
11.2 South America Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market size Outlook by Segments, 2021-2030
By Product
Patch Pumps
-Basal
-Bous
-Basal and bolus
Tethered pumps
-Insulin reservoir and cartridges
-Insulin set insertion devices
-Battery
By Patient
Type 1 diabetes
Type 2 diabetes
12 Middle East and Africa Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Continuous Subcutaneous Insulin Therapy Devices (CSITD) Markets in 2024
12.2 Middle East and Africa Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market size Outlook by Segments, 2021-2030
By Product
Patch Pumps
-Basal
-Bous
-Basal and bolus
Tethered pumps
-Insulin reservoir and cartridges
-Insulin set insertion devices
-Battery
By Patient
Type 1 diabetes
Type 2 diabetes
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Cellenovo
CeQur
F. Hoffmann-La Roche Ltd
Insulet Corp
Medtronic Plc
Sooil Development
Tandem Diabetes Care
Valeritas Inc
Ypsomed
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Patch Pumps
-Basal
-Bous
-Basal and bolus
Tethered pumps
-Insulin reservoir and cartridges
-Insulin set insertion devices
-Battery
By Patient
Type 1 diabetes
Type 2 diabetes